Compare DSWL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSWL | EQ |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 64.5M |
| IPO Year | 1995 | 2018 |
| Metric | DSWL | EQ |
|---|---|---|
| Price | $3.35 | $1.39 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 13.4K | ★ 657.9K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | ★ 6.08% | N/A |
| EPS Growth | ★ 20.23 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $65,664,000.00 | $4,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.93 | $0.27 |
| 52 Week High | $4.48 | $2.35 |
| Indicator | DSWL | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 57.77 |
| Support Level | $3.00 | $1.17 |
| Resistance Level | $3.43 | $1.32 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 72.92 | 97.10 |
Deswell Industries Inc is engaged in the manufacturing and selling of injection-molded plastic parts and components. In addition, it also offers manufacturing services for electronic products and subassemblies and manufactures metallic molds and accessory parts for original equipment manufacturers and contract manufacturers. The company conducts all of its manufacturing activities at separate plastics, electronics and metallic operation factories located in the People's Republic of China. It operates through the Plastic Injection Molding and Electronic Products Assembling segments. The firm offers products such as automobile components, medical testing equipment, parts for audio equipment, av receivers, active subwoofers, digital system key sets, communication products and others.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.